As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Moderna (NASDAQ:MRNA) and its peers.
Curious about the top performers within the S&P500 index one hour before the close of the markets on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Shares of biotechnology company Moderna (NASDAQ:MRNA)
fell 3.6% in the morning session after JPMorgan added the stock to its list of top short ideas for the second half of 2025.
Top performers last week: Venture Global up 18.96% on LNG deal, SoFi up 14.29% on analyst coverage, Delta up 11.91% on earnings, Unity up 9.17% on price forecast, Moderna up 10.66% on FDA approval, PTC up 10.06% on acquisition rumors.
A number of stocks fell in the morning session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
A growing chorus of lawmakers, ethics watchdogs, and concerned citizens are reigniting a high-stakes debate: Should U.S. politicians be allowed to buy and sell stocks while in office?
Amidst rising public distrust and a series of high-profile investigations into lawmakers' financial dealings, calls to ban or heavily restrict stock
Shares of biotechnology company Moderna (NASDAQ:MRNA)
jumped 3.8% in the morning session after the U.S. Food and Drug Administration (FDA) granted full approval for its Spikevax COVID-19 vaccine to be used in children. The approval covers children from six months through 11 years of age who are at an elevated risk for severe COVID-19.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.
The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.
FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid concerns about rare side effects.
